Research ArticleArticle
Open Access
Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study
Frank Behrens, Michaela Koehm, Uta Arndt, Bianca M. Wittig, Gerd Greger, Diamant Thaçi, Eva Scharbatke, Hans-Peter Tony and Harald Burkhardt
The Journal of Rheumatology December 2015, jrheum.141596; DOI: https://doi.org/10.3899/jrheum.141596
Frank Behrens
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Michaela Koehm
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Uta Arndt
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Bianca M. Wittig
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Gerd Greger
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Diamant Thaçi
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Eva Scharbatke
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Hans-Peter Tony
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Harald Burkhardt
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Article Information
jrheum.141596
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online December 15, 2015.
Article Versions
- You are currently viewing a Latest version of this article (December 15, 2015 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2015 The Journal of Rheumatology
Author Information
- Frank Behrens,
- Michaela Koehm,
- Uta Arndt,
- Bianca M. Wittig,
- Gerd Greger,
- Diamant Thaçi,
- Eva Scharbatke,
- Hans-Peter Tony and
- Harald Burkhardt
- From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG).
F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg.
Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de.
Full Release Article. For details see Reprints/Permissions at jrheum.org.
Accepted for publication September 1, 2015.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study
Frank Behrens, Michaela Koehm, Uta Arndt, Bianca M. Wittig, Gerd Greger, Diamant Thaçi, Eva Scharbatke, Hans-Peter Tony, Harald Burkhardt
The Journal of Rheumatology Dec 2015, jrheum.141596; DOI: 10.3899/jrheum.141596
Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study
Frank Behrens, Michaela Koehm, Uta Arndt, Bianca M. Wittig, Gerd Greger, Diamant Thaçi, Eva Scharbatke, Hans-Peter Tony, Harald Burkhardt
The Journal of Rheumatology Dec 2015, jrheum.141596; DOI: 10.3899/jrheum.141596